Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

Ítems similars

• CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
  per: Cannady, Ellen A., et al.
  Publicat: (2015)
• Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults
  per: Suico, Jeffrey G, et al.
  Publicat: (2014)
• A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
  per: Small, David S., et al.
  Publicat: (2015)
• Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
  per: Small, David S., et al.
  Publicat: (2016)
• Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
  per: Cannady, Ellen A., et al.
  Publicat: (2015)